ST PHARM Participates in DCAT Week 2025, Seeking Global Partnerships

- Continuing participation following last year, aiming to attract global clients

ST PHARM announced on March 21st that it participated in the Drug, Chemical & Associated Technologies (DCAT) Week 2025, held in New York City from March 17th to 20th.

DCAT Week, which began in 1890 under the auspices of the New York Chamber of Commerce, is a premier event in the pharmaceutical and biotech sectors with over 150 years of tradition. The event is well-known for providing various forms of B2B partnering meetings, especially as it attracts high-level executives with decision-making authority, making it a key platform for exploring new partnerships.

Led by its executive team, ST PHARM highlighted its core competencies during the event, including its strong oligonucleotide manufacturing capabilities and the progress of its Second Oligo Plant Expansion, which is set to begin full operation in the fourth quarter of this year.

Through these efforts, ST PHARM expects to further solidify partnerships with existing oligonucleotide clients while advancing discussions on various ongoing projects.

Additionally, ST PHARM’s CRISPR CDMO service offerings will be featured in the April issue of the DCAT online magazine, DCAT Value Chain Insights. The article will cover the company’s expansion of its mRNA facilities in the first half of 2025 to support CRISPR CDMO services, including its proprietary 5'-capping technology, lipid nanoparticle (LNP)-based drug delivery systems (DDS), and high-quality guide RNA (gRNA) production technology. These innovations aim to accelerate the development of next-generation CRISPR-based therapeutics.

Previously, ST PHARM was selected as one of the presenting companies at last year’s DCAT Member Company Announcement Forum, where it shared updates on the Second Oligo Plant Expansion and its RNA platform technology.

A representative from ST PHARM stated, “We conducted face-to-face meetings with numerous existing and potential clients, discussing partnerships across various fields such as oligonucleotides, monomers, and synthetic new drugs. We will continue to promote the growth potential of our Second Oligo Plant and strengthen partnerships on the global stage.”